2seventy bio, Inc. is a cell and gene therapy company, which is focused on the research, development and commercialization of transformative treatments for cancer. The Company is advancing multiple clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia, and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, as well as multiple preclinical programs, including bbT4015, an engineered chimeric antigen receptor (CAR) T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb (BMS), the Company is delivering ABECMA to multiple myeloma patients in the United States for the treatment of adults with multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and a cyclic ADP ribose hydrolase (anti-CD38) monoclonal antibody.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)